{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:12:53Z","timestamp":1791295973652,"version":"4.1.0"},"reference-count":15,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2004,7,23]],"date-time":"2004-07-23T00:00:00Z","timestamp":1090540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2004,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Increased adhesive events between the blood vessel endothelium and red and white cells play a central role in the initiation of vasoocclusive crisis in sickle cell disease (SCD). Soluble VCAM\u20101 levels are increased in the plasma of sickle cell patients and may be reduced during hydroxyurea (HU) therapy. Reports regarding any changes in soluble ICAM\u20101 (sICAM\u20101) levels in sickle cell patients, however, are conflicting, and as yet no beneficial effect of HU upon levels has been observed. Thus, we sought to thoroughly investigate changes in sICAM\u20101 levels in SCD patients and the effect of HU therapy (20\u201330 mg\/kg\/day). Plasma sVCAM\u20101 levels were significantly higher in steady\u2010state SCD patients than in normal controls (766 \u00b1 86 ng\/mL vs. 325 \u00b1 38 ng\/mL, respectively, <jats:italic>P<\/jats:italic> &lt; 0.0001). sVCAM\u20101 levels were decreased in patients on HU therapy (543 \u00b1 69 ng\/mL) compared to those not taking HU; however, this difference was not significant. Plasma sICAM\u20101 levels were significantly increased in steady\u2010state SCD patients compared to normal individuals (285 \u00b1 20 ng\/mL vs. 202 \u00b1 16 ng\/mL, respectively, <jats:italic>P<\/jats:italic> = 0.002), and HU therapy significantly reduced sICAM\u20101 levels in patients (217 \u00b1 12, <jats:italic>P<\/jats:italic> = 0.027) to levels approaching those of healthy individuals. sVCAM\u20101 levels inversely correlated with fetal hemoglobin levels in SCD patients, while a nonsignificant inverse trend was observed between sICAM\u20101 levels and fetal hemoglobin. In conclusion, plasma sICAM\u20101 levels were significantly increased in SCD patients, and this increase was reversed by hydroxyurea therapy, possibly reflecting reduced endothelial activation in patients taking HU. Such an event may benefit patients by reducing adhesive interactions between white cells and the endothelium. Am. J. Hematol. 76:343\u2013347, 2004. \u00a9 2004 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ajh.20129","type":"journal-article","created":{"date-parts":[[2004,7,23]],"date-time":"2004-07-23T17:03:17Z","timestamp":1090602197000},"page":"343-347","source":"Crossref","is-referenced-by-count":42,"title":["Increased levels of soluble ICAM\u20101 in the plasma of sickle cell patients are reversed by hydroxyurea"],"prefix":"10.1002","volume":"76","author":[{"given":"Nicola","family":"Conran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Fattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara T.O.","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando F.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,7,23]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119442"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.1.266"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199711273372203"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/346425a0"},{"key":"e_1_2_1_6_2","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1182\/blood.V95.10.3232","article-title":"Perfusion with sickle erythrocytes up\u2010regulates ICAM\u20101 and VCAM\u20101 gene expression in cultured human endothelial cells","volume":"95","author":"Shiu YT","year":"2000","journal-title":"Blood"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03274.x"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1006\/clin.1996.0163"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.7.2297"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1159\/000040964"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5849(00)00223-9"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199505183322001"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09776-3"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0037-1963(01)90027-7"},{"key":"e_1_2_1_15_2","first-page":"818","article-title":"Inhibition of endothelial cell activation by nitric oxide donors","volume":"295","author":"Zampolli A","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"e_1_2_1_16_2","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1007\/BF03401964","article-title":"Nitric oxide inhibits endothelial IL\u20101[beta]\u2010induced ICAM\u20101 gene expression at the transcriptional level decreasing Sp1 and AP\u20101 activity","volume":"7","author":"Berendji\u2010Grun D","year":"2001","journal-title":"Mol Med"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.20129","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.20129","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T02:16:12Z","timestamp":1700187372000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.20129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7,23]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["10.1002\/ajh.20129"],"URL":"https:\/\/doi.org\/10.1002\/ajh.20129","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,7,23]]}}}